These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. Ferretti G; Fabi A; Felici A; Papaldo P J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395 [No Abstract] [Full Text] [Related]
5. HER2 status and benefit from adjuvant trastuzumab in breast cancer. Paik S; Kim C; Wolmark N N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751 [No Abstract] [Full Text] [Related]
6. Trastuzumab in the treatment of breast cancer. Hortobagyi GN N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745 [No Abstract] [Full Text] [Related]
7. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746 [TBL] [Abstract][Full Text] [Related]
8. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Tokuda Y; Suzuki Y; Saito Y; Umemura S Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625 [No Abstract] [Full Text] [Related]
12. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer. Liao C; Yin F; Huang P; Cao Y; Gao F Breast J; 2011; 17(1):109-11. PubMed ID: 21129096 [No Abstract] [Full Text] [Related]
13. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study]. Mallmann P Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017 [No Abstract] [Full Text] [Related]
15. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. Roukos DH J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920 [No Abstract] [Full Text] [Related]
16. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer]. Heinzl S Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587 [No Abstract] [Full Text] [Related]
17. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy. Fox KF Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943 [No Abstract] [Full Text] [Related]
19. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab? Araki K; Pegram M Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800 [No Abstract] [Full Text] [Related]